Cargando…

Changes in Patient Reported Pain Measures With the Citrate-free Adalimumab Formulation in Pediatric Inflammatory Bowel Disease Patients

Inflammatory bowel diseases (IBD) are characterized by chronic inflammation in the gastrointestinal tract. The perception of pain in children is very complex and involves psychological, physiological, behavioral, and developmental factors. For children with chronic diseases, the medical procedures a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Ashish S., Luu, Phuong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins, Inc. 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191498/ https://www.ncbi.nlm.nih.gov/pubmed/37206609 http://dx.doi.org/10.1097/PG9.0000000000000016

Ejemplares similares

Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States
por: Bergman, Martin, et al.
Publicado: (2020)

Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022)

Effect of different lipids and surfactants on formulation of solid lipid nanoparticles incorporating tamoxifen citrate
por: Upadhyay, S. U., et al.
Publicado: (2012)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Tuberculosis Cutis Orificialis in Adalimumab Related Immunosupressive Patient
por: Iskandarli, Mehdi, et al.
Publicado: (2017)

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
por: Park, Sung Eun, et al.
Publicado: (2021)

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)

Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease
por: Marquez-Megias, Silvia, et al.
Publicado: (2021)

Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
por: Chabra, Sanjay, et al.
Publicado: (2022)

Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Sunny, Julee, et al.
Publicado: (2022)

Recent advances in understanding and managing pediatric inflammatory bowel disease
por: Gurram, Bhaskar, et al.
Publicado: (2019)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
por: Mocci, Giammarco, et al.
Publicado: (2022)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection
por: Lwin, Nilar, et al.
Publicado: (2018)

Adalimumab for refractory peripheral ulcerative keratitis
por: Cordero-Coma, Miguel, et al.
Publicado: (2012)

Barriers From Third-Party Payers to Biologic Use in Pediatric Inflammatory Bowel Disease
por: Lepus, Chelsea A., et al.
Publicado: (2022)

A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents
por: Junker, Sophia, et al.
Publicado: (2023)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)
por: Ahn, So-shin, et al.
Publicado: (2022)

Inflammatory Bowel Disease
por: Lee, Shona J., et al.
Publicado: (2014)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Eruptive Benign Melanocytic Nevi Formation Following Adalimumab Therapy in a Patient with Crohn's Disease
por: Moon, Ik Jun, et al.
Publicado: (2016)

A case report of adalimumab-associated optic neuritis
por: Kim, Alice, et al.
Publicado: (2012)

Should Asian inflammatory bowel disease patients need routine thromboprophylaxis?
por: Weng, Meng-Tzu, et al.
Publicado: (2018)

Attitudes towards COVID‐19 vaccination in patients with inflammatory bowel disease
por: Duong, Tuan A., et al.
Publicado: (2022)

Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
por: Alameddine, Zakaria, et al.
Publicado: (2023)

Fixed Drug Eruption Caused by Sildenafil Citrate
por: Choi, Sun Young, et al.
Publicado: (2017)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
por: Chang, Chen-Wang, et al.
Publicado: (2014)

Adverse Events Related to SARS-CoV-2 Vaccine in a Nationwide Cohort of Patients With Inflammatory Bowel Disease
por: Mahmud, Nadim, et al.
Publicado: (2022)

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
por: Gubatan, John, et al.
Publicado: (2020)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017)

A clinical study to compare the efficacy and safety of pregabalin sustained release formulation with pregabalin immediate release formulation in patients of diabetic peripheral neuropathic pain
por: Srivastava, A., et al.
Publicado: (2012)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
por: Lin, Wei-Chen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_urpussfcc1ejvglipt4jkn2ltd